ARVN logo

ARVINAS INC

ARVNNASDAQ
🏆 #2882 by market capEarnings Nov 3 · PreUS Equity
——
Quote unavailable
🔔
Track ARVN
Get earnings, price moves & breaking news on Telegram
Track
24h—
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$487M
Small Cap
📈Revenue Growth (YoY)
-15.1%
Declining
📊Gross Margin
—
💵FCF Margin
15.7%
Healthy
⚖️P/S Ratio
1.5x
Cheap
Otter Score
—
Insufficient data
No chart data available for ARVN.

Trading Snapshot

Day Range
—
52-Week Range
$6.74 – $14.51
Volume (shares)
—
Avg Volume (shares)
—
Shares Outstanding
65.4M
Next Earnings
2026-11-03

Fundamentals Snapshot

Annual Revenue
$263M
Last Q Revenue
$250M
P/E Ratio
52.1
P/S Ratio
1.5x
EPS (TTM)
$0.16
Dividend Yield
—
Dilution (1yr)
−10.0%
ARVN logo

ARVINAS INC

ARVN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$263M▼ −0.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
98.0%▼ −2.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$115M▼ −54.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$276M▲ +5.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
64.9M▼ −10.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$134M▲ +$43M YoY
StockOtter · stockotter.space

About ARVINAS INC

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst data unavailable.

Latest News & Updates

News unavailable.